Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Bristol Myers Squibb (BMY) announced on Tuesday that a late-stage study evaluating Iberdomide in patients with relapsed or ...

In the cancer type multiple myeloma, the malignant cells differ significantly from normal cells regarding the layer of ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma ...

Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can ...

Today, the Multiple Myeloma Research Foundation® (MMRF) announced that data generated from several MMRF initiatives were presented at the prestigious 22 nd International Myeloma Society (IMS) Annual ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy ...

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies. The SWIFT-seq method, which employs single-cell sequencing to profile circulating tumor cells ...

Among 78 patients with relapsed or refractory disease, the 24-month relapse-free rate after treatment discontinuation was 68% ...